678-515-0585 info@drdahlman.com

I am often asked for any studies that have been done on my protocols for the purpose of adding credibility to my advice. No one has studied “my” exact treatment plans. My treatment plans are a compilation of many studies that have already been done. I have simply connected the dots and designed a successful protocol.


  1. “Horwittz BJ, Fisher RS. The irritable bowel syndrome. New Engl J Med 2001;344(24):1846-50.”
  2. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999;107(5A):12S-19S.
  3. “Mielants H, De Vos M, Goemaere S, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J Rheumatol 1991;18(3):394-400.”
  4. “Smith M, Gibson R, Brooks P. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1985;12(2):299-305.”
  5. “Andre C, Andre F, Colin L. Effect of allergen ingestion challenge with and without cromoglycate cover on intestinal permeability in atopic dermatitis, urticaria, and other symptoms of food allergy. Allergy 1989;44 (Suppl 9):47-51.”
  6. “Isolauri E, Juntunen M, Wiren S. Intestinal permeability changed in acute gastroenteritis: effects of clinical factors and nutritional management. J Pediatr Gastroenterol Nutr 1989;8(4):466-73.”
  7. “Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn?s disease and ulcerative colitis and their first degree relatives. Gut 1994;35(1):68-72.”
  8. “Olaison G, Sjodahl R, Tagesson C. Abnormal intestinal permeability in Crohn?s disease. Scand J Gastroenterol 1990;25(4):321-28.”
  9. McCarthy DM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999;107(6A):37S-46S.
  10. “Sicherer SH. Manifestations of food allergy: evaluation and management. Am Fam Physician 1999; 59(2):415-24, 429-30.”
  11. “Samartín S, Marcos A, Chandra RK. Food hypersensitivity. Nutr Res 2001;21(3):473-97.”
  12. “Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999;104(3 Pt 2):S114-22.”
  13. “Fraser AG, Woollard GA. Gastric juice ascorbic acid is related to Helicobacter pylori infection but not ethnicity. J Gastroenterol Hepatol 1999;14(11):1070-73.”
  14. “Reed PI. Vitamin C, Helicobacter pylori infection and gastric carcinogenesis. Int J Vitam Nutr Res 1999;69(3):220-27.”
  15. “Fleming C, Huizenga K, McCall J, et al. Zinc nutrition in Crohn?s disease. Dig Dis Sci 1991;26(10):865-70.”
  16. “Hendricks K, Walder W. Zinc deficiency in inflammatory bowel disease. Nutr Rev 1988;46(12):401-08.”
  17. Tomomatsu H. Health effects of oligosaccharides. Food Tech 1994;October:61-65.
  18. “Gibson G, Roberfroid M. Dietary modulation of the human colonic microbiota: introducing the concept of probiotics. J Nutr 1995;125(6):1401-12.”
  19. Roberfroid MB. Chicory fructooligosaccharides and the gastrointestinal tract. Nutrition 2000;16(7-8):677-79.
  20. “Robinson R, Causey J, Slavin JL. Nutritional benefits of larch arabinogalactan. In: ed. McCleary BV, Prosky L. Advanced Dietary Fibre Technology. London: Blackwell Science; 2001:443-51.”
  21. “Ellestad-Sayed J, Nelson R, Adson M, et al. Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis. Am J Clin Nutr 1976;29:1333-38.”
  22. “Lacroix B, Didier E, Grenier J. Role of pantothenic and ascorbic acid in wound healing processes: in vitro study on fibroblasts. Intl J Vit Nutr Res 1988;58:507-13.”
  23. “Lewis DA, Shaw GP. A natural flavonoid and synthetic analogues protect the gastric mucosa from aspirin-induced erosions. J Nutr Biochem 2001;12(2):85-100.”
  24. “Mukhopadhyaya K, Bhattacharya D, Chakraborty A, et al. Effect of banana powder (Musa sapeintus var. paradisiaca) on gastric mucosal shedding. J Ethnopharmacol 1987;21(1):11-19.”
  25. “Wakabayashi H, Orihara T, Nakaya A, et al. Effect of Helicobacter pylori infection on gastric mucosal phospholipid contents and their fatty acid composition. J Gastrenterol Hepatol 1998;13(6):566-71.”
  26. “Kurinets A, Lichtenberger LM. Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. Dig Dis Sci 1998;43(4):786-90.”
  27. “Anand BS, Romero JJ, Sanduja SK, et al. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am Coll Gastroenterol 1999;94(7):1818-22.”
  28. “Ziegler TR, Bazargan N, Leader LM, et al. Glutamine and the gastrointestinal tract. Curr Opin Clin Nutr Metab Care 2000;3(5):355-62.”
  29. “Klimberg VS, Salloum RM, Kasper M, et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg 1990;125(8):1040-45.”
  30. “Souba WW, Klimberg VS, Plumley DA, et al. The role of glutamine in maintaining a health gut and supporting the metabolic response to injury and infection. J Surgical Res 1990;48(4):383-91.”
  31. “Cao Y, Feng Z, Hoos A, et al. Glutamine enhances gut glutathione production. J Parent Enteral Nutr 1998;22(4):224-27.”
  32. “LeLeiko NS, Walsh MJ. The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. Pediatr Clin North Am 1996;43(2):451-70.”
  33. “Nakajima M, Shinoda I, Samejima Y, et al. Lactoferrin as a suppressor of cell migration of gastrointestinal cell lines. J Cell Physiol 1997;170(2):101-05.”
  34. “Kruzel ML, Harari Y, Chen C-Y, et al. The gut: a key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol 1998;443:167-73.”
  35. “Kussendrager KD, van Hooijdonk AC. Lactoperoxidase: physico-chemical properties, occurrence, mechanism of action and applications. Br J Nutr 2000;84 (Suppl 1):S19-25.”
  36. “van Hooijdonk AC, Kussendrager KD, Steijns JM. In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence. Br J Nutr 2000;84 (Suppl 1):S127-34.”
  37. “Hauer J, Anderer FE. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. Cancer Immunol Immunother 1993;36(4):237-44.”
  38. Kelly GS. Larch arabinogalactan: Clinical relevance of a novel immune-enhancing polysaccharide. Alt Med Rev. 1999;4(2):96-103.
  39. “Hagmar B, Ryd W, Skomedal H. Arabinogalactan blockade of experimental metastases to liver by murine hepatoma. Invasion Metastasis 1991;11(6):348-55.”
  40. “Vince AJ, McNeil NI, Wager JD, et al, The effect of lactulose. pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system. Br J Nutr 1990;63(1):17-26.”
  41. “Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. Annu Rev Med 2001;52:319-38.”
  42. Borum ML. Irritable bowel syndrome. Gastroenterology 2001;28(3):523-38.
  43. “Browning SM. Constipation, diarrhea, and irritable bowel syndrome. Prim Care 1999;26(1):113-39.”
  44. Schuster MM. Defining and diagnosing irritable bowel syndrome. Amer J Man Care 2001;7(Suppl):S247-51.
  45. “National Institute of Diabetes & Digestive & Kidney Diseases. Irritable bowel syndrome. (1992, October). Retrieved February 5, 2002, from http://www.niddk.nih.gov/health/digest/pubs/irrbowel/irrbowel.htm”
  46. “Horwitz BJ, Fisher RS. The irritable bowel syndrome. New Engl J Med 2001;344(24);1846-50.”
  47. “Schulz V, Hansel R, Tyler VE. Rational Phytotherapy, A Physicians? Guide to Herbal Medicine. 3rd ed. Berlin: Springer-Verlag; 1998.”
  48. “Kline RM, Kline JJ, Di Palma J, et al. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pedriatr 2001;138(1):125-28.”
  49. “Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32(6):765-68.”
  50. “Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastro-intestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991;101(1):55-65.”
  51. “O?Hara MA, Kiefer D, Farrell K, et al. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998;7(6):523-36.”
  52. “Lis-Balchin M, Hart S. Studies on the mode of action of the essential oil of lavender (Lavandula angustifolia P. Miller). Phytother Res 1999;13(6):540-42.”
  53. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 2001;7(2):136-45.
  54. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 2001;7(2):136-45.
  55. Reid G. In vitro testing of Lactobacillus acidophilus NCFM as a possible probiotic for the urogenital tract. Int Dairy J 2000;10:415-19.
  56. “Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001;73(suppl):451S-55S.”
  57. “Sanders ME, Klaenhammer TR. The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 2001;84:319-31.”
  58. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999;3(4):197-202.
  59. “Goldin BR, Swenson L, Dwyer J, et al. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Instit 1980;64:255-61.”
  60. “Gilliland SE, Speck ML. Antagonistic action of Lactobacillus acidophilus toward intestinal and food borne pathogens in associative cultures. J Food Protection 1977;40(12):820-23.”
  61. “Schauss AG. Lactobacillus acidophilus: method of action, clinical application, and toxicity data. J Adv Med 1990;3(3):163-78.”
  62. “Lin MY, Savaiano D, Harlander S. Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans. J Dairy Sci 1991;74:87-95.”
  63. “Barefoot SF, Klaenhammer TR. Detection and activity of lactacin B, a bacteriocin produced by Lactobacillus acidophilus. Appl Environ Microbiol 1983;45:1808-15.”
  64. “Barefoot SF, Chen YR, Hughes TA, et al. Identification and purification of a protein that induces production of the Lactobacillus acidophilus bacteriocin lactacin B. Appl Environ Microbiol 1994;60:3522-28.”
  65. “Goldin BR, Gorbach SL. The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme activity. Amer J Clin Nutr 1984;39:756-61.”
  66. “Goldin BR, Gorbach SL. Alterations of the intestinal microflora by diet, oral antibiotics, and Lactobacillus: decreased production of free amines from aromatic nitro compounds, azo dyes, and glucuronides. J Natl Cancer Instit 1984;73:689-95.”
  67. “Goldin BR, Gorbach SL. Effect of Lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. J Natl Cancer Instit 1980;64:263-65.”
  68. “Simenhoff ML, Dunn SR, Zollner GP, et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996;22:92-96.”
  69. “Kim GS, Gilliland SE. Lactobacillus acidophilus as a dietary adjunct for milk to aid lactose digestion in humans. J Dairy Sci 1983;66:959-66.”
  70. “Marteau PR, de Vrese M, Cellier CJ, et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73(suppl):430S-36S.”
  71. “Walker DK, Gilliland SE. Relationships among bile tolerance, bile salt deconjugation, and assimilation of cholesterol by Lactobacillus acidophilus. J Dairy Sci 1993;76:956-61.”
  72. “Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 1985;49:377-81.”
  73. “Cassell GH, Mekalanos J. Antibiotic resistance. JAMA 2001;285:601-05.”
  74. “Tuomola E, Crittenden R, Playne M, et al. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001;73(suppl):393S-98S.”
  75. Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol 1999;65(9):3763-66.
  76. “Gilliland SE, Walker DK. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci 1990;73:905-11.”
  77. “Kleeman EG, Klaenhammer TR. Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci 1982;65:2063-69.”
  78. “Montes RG, Bayless TM, Saavedra JM. Effect of milks inoculated with Lactobacillus acidophilus or a yogurt starter culture in lactose-maldigesting children. J Dairy Sci 1995;78(8):1657-64.”
  79. “Greene JD, Klaenhammer TR. Factors involved in adherence of lactobacilli to human caco-2 cells. Appl Environ Microbiol 1994;60:4487-94.”
  80. “Gilliland SW, Speck ML, Nauyok DF, et al. Influence of consuming nonfermented milk containing Lactobacillus acidophilus on fecal flora of healthy males. J Dairy Sci 1978;61:1-10.”
  81. “Sanders ME, Walker DC, Walker KM, et al. Performance of commercial cultures in fluid milk applications. J Dairy Sci 1996;79:943-55.”
  82. “Klaenhammer TR, Kleeman EG. Growth characteristics, bile sensitivity, and freeze damage in colonial variants of Lactobacillus acidophilus. Appl Environ Microbiol 1981;41:1461-67.”
  83. Klaenhammer TR. Microbiological considerations in selection and preparation of Lactobacillus strains for use as dietary adjuncts. J Dairy Sci 1982;65:1339-49.
  84. “Goldin B, Gorbach SL. Alterations in fecal microflora enzymes related to diet, age, Lactobacillus supplements, and dimethylhydrazine. Cancer 1977;40:2421-26.”
  85. “Kaplan H, Hutkins RW. Fermentation of fructooligosaccharides by lactic acid bacteria and bifidobacteria. Appl Environ Microbiol 2000;66(6):2682-84.”
  86. “Rasic JLj, Kurmann JA. Bifidobacteria and Their Role. Boston: Kirkhauser Verlag; 1983.”
  87. “Gill HS, Rutherfurd KJ, Cross ML, et al. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001;74(6):833-39.”
  88. “Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401-12.”
  89. Guyton AC. Protein Metabolism. In: Textbook of Medical Physiology. 8th ed. Philadelphia: W.B. Saunders; 1991.
  90. “Ward PP, Uribe-Luna S, Conneely OM. Lactoferrin and host defense. Biochem Cell Biol 2002;80(1):95-102.”
  91. Ellison RT 3rd. The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol 1994;357:71-90.
  92. Conneely OM. Antiinflammatory activities of lactoferrin. J Am Coll Nutr 2001;20(5 Suppl):389S-97S.
  93. “van der Strate BW, Beljaars L, Molema G, et al. Antiviral activities of lactoferrin. Antiviral Res 2001;52(3):225-39.”
  94. “Ajello M, Greco R, Giansanti F, et al. Anti-invasive activity of bovine lactoferrin towards group A streptococci. Biochem Cell Biol 2002;80(1):119-24.”
  95. “Shin K, Hayasawa H, Lonnerdal B. Inhibition of Escherichia coli respiratory enzymes by the lactoperoxidase-hydrogen peroxide-thiocyanate antimicrobial system. J Appl Microbiol 2001;90(4):489-93.”
  96. “Shin K, Yamauchi K, Teraguchi S, et al. Susceptibility of Helicobacter pylori and its urease activity to the peroxidase-hydrogen peroxide-thiocyanate antimicrobial system. J Med Microbiol 2002;51(3):231-37.”
  97. “Borch E, Rosen C, Bjorck L. Antibacterial effect of the lactoperoxidase/thiocyanate/hydrogen peroxide system against strains of campylobacter isolated from poultry. J Food Protect 1989;42(9):639-41.”
  98. “Thomas EL, Milligan TW, Joyner RE, et al. Antibacterial activity of hydrogen peroxide and the lactoperoxidase-hydrogen peroxide-thiocyanate system against oral streptococci. Infect Imm 1994;6(2):529-35.”
  99. “Lengerich EJ, Addiss DG. Severe giardiasis in the United States. Clin Infec Dis 1994;18:760-63.”
  100. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46-53.
  101. “Bensky D, Gamble A. Chinese Herbal Medicine. Materia Medica. Seattle: Eastland Press; 1986.”
  102. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999;12(4):564-82.
  103. Duke JA. Handbook of Medicinal Herbs. Boca Raton: CRC Press; 1985.
  104. “Shils ME, Olson JA, Shike M, et al. editors. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Williams & Wilkins; 1999.”
  105. Wallace JM. Nutritional modulation of gut-immune system interactions in autoimmunity. Int J Integr Med 2000;2(1):18-22.
  106. “Slocum MM, Sittig MD, Specian RD, et al. Absence of intestinal bile promotes bacterial translocation. Am Surg 1992;58:305-10.”
  107. “Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353(9167):1838-42.”
  108. “Knoke M, Bernhardt H. The impact of microbial ecology on clinical problems. Infection 1989;17(4):255-58.”
  109. “Veys EM, Mielants H. Enteropathic arthritis, uveitis, Whipple?s disease, and miscellaneous spondyloarthropathies. Curr Opin Rheumatol 1993;5(4):420-27.”
  110. “Gorbach SL. Estrogens, breast cancer, and intestinal flora. Rev Infect Dis 1984;6(1):S85-S90.”
  111. “McDowell RM, McElvaine MD. Long-term sequelae of foodborne diseases. Rev Sci Tech 1997;16(2):337-41.”
  112. “Galland L, Barrie S. Intestinal dysbiosis and the causes of disease. J Adv Med 1993;6(2):67-81.”
  113. “Heumann D, Glauser MP. Pathogenesis of sepsis. Sci Am 1994;1:28-37.”
  114. “Rowlands BJ, Gardiner KR. Nutritional modulation of gut inflammation. Proc Nutr Soc 1998;57(3):395-401.”
  115. “Research on host susceptibility to emerging pathogens. (n.d.). National Institutes of Health, National Institute of Allergy and Infectious Disease. Retrieved April 3, 2000, from http://www.niaid.nih.gov/publications/execsum/3a.htm”
  116. “Skov L, Baadsgaard O. Superantigens. Do they have a role in skin disease? Arch Dermatol 1995;131(7):829-32.”
  117. “Torres BA, Johnson HM. Modulation of disease by superantigens. Curr Opin Immunol 1998;10(4):465-70.”
  118. “Soos JM, Schiffenbauer J, Torres BA, et al. Superantigens as virulence factors in autoimmunity and immunodeficiency diseases. Med Hypotheses 1997;48(3):253-59.”
  119. “Johnson HM, Torres BA, Soos JM. Superantigens:structure and relevance to human disease. Soc Exp Biol Med 1996;212:99-109.”
  120. “Gladwin M, Trattler B. Clinical Microbiology Made Ridiculously Simple. Miami: MedMaster, Inc.; 1995.”
  121. “Dharmananda S. Chinese Herbology: A Prefessional Training Progrram. Portland, Oregon: Institute for Traditional and Preventative Health Care; 1992.”
  122. Chevallier A. The Encyclopedia of Medicinal Plants. London: Dorling Kindersley Ltd.; 1996.
  123. Huang KC. The Pharmacology of Chinese Herbs. Boca Raton: CRC Press; 1993.
  124. “Tyler VE, Brady LR, Robbers, JE. Pharmacognosy. 9th ed. Philadelphia: Lea & Febiger; 1988.”
  125. “Wang M, Shao Y, Li J, et al. Antioxidative phenolic glycosides from sage (Salvia officinalis). J Nat Prod 1999;62(3):454-56.”
  126. “Agnihotri S, Vaidya ADB. A novel approach to study antibacterial properties of volatile components of selected Indian medicinal herbs. Indian J Exp Biol 1996;34:712-15.”
  127. “Tabak M, Armon R, Potaman I, et al. In vitro inhibition of Helicobacter pylori by extracts of thyme. J Appl Bacteriol 1996;80(6):667-72.”
  128. “Smith-Palmer A, Stewart J, Fyfe L. Antimicrobial properties of plant essential oils and essences against five important food-borne pathogens. Lett Appl Microbiol 1998;26(2):118-22.”
  129. “Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oils and other plant extracts. J Appl Microbiol 1999;86(6):985-90.”
  130. “Dorman HJ, Deans SG. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J Appl Microbiol 2000; 88(2):308-16.”
  131. “Milhau G, Valentin A, Benoit F, et al. In vitro antimalarial activity of eight essential oils. J Essent Oil Res 1997;9:329-33.”
  132. “Blumenthal M, BusseWR, Goldberg A, et al. editors. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, Texas: American Botanical Society; 1998.”
  133. “Kucera LS, Cohen RA, Herrmann EC. Antiviral activities of extracts of the lemon balm plant. Ann N Y Acad Sci 1965;130(1):474-82.”
  134. “Kaneda Y, Torii M, Tanaka T, et al. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. Annals Trop Med Parasitology 1991;85(4):417-25.”
  135. “Rabbani GH, Butler T, Knight J, et al. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Eschericia coli and Vibrio cholerae. J Infec Dis 1987;155(5):979-84.”
  136. “Sy ND, Hoan DB, Dung NP, et al. Treatment of malaria in Vietnam with oral artemisinin. Am J Trop Med Hyg 1993;48(3):398-402.”
  137. “Koch HP, Lawson LD, editors. Garlic: The Science and Therapeutic Application of Allium sativum L. and Related Species. 2nd Ed. Baltimore: Williams & Wilkins; 1996.”
  138. “Ankri S, Mirelman D. Antimicrobial properties of allicin from garlic. Microbes Infect 1999;1(2):125-29.”
  139. “Mascolo N, Jain R, Jain SC, et al. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol 1989;27:129-40.”
  140. “Adewunni CO, Oguntimein BO, Furu P. Molluscicidal and antischistosomal activities of Zingiber officinale. Planta Med 1990;36:374-76.”
  141. “Yamahara J, Huang Q, Li Y, et al. Gastrointestinal motility enhancing effect of ginger and its active constituents. Chem Pharm Bull 1990;38(2):430-31.”
  142. “Goto C, Kasuya S, Koga K, et al. Lethal efficacy of extract from Zingiber officinale (traditional Chinese medicine) or [6]-shogaol and [6]-gingerol in Anisakis larvae in vitro. Parisitol Res 1990;76:653-56.”
  143. “Rhee JK, Woo KJ, Baek BK, et al. Screening of the wormicidal Chinese raw drugs on Clonorchis sinensis. Am J Chin Med 1982;9(4):277-84.”
  144. “Duthie SJ, Collins AR, Duthie GG, Dobson VL. Quercetin and myricetin protect against hydrogen peroxide-induced DNA damage (strand breaks and oxidised pyrimidines) in human lymphocytes. Mutat Res. 1997;393(3):223-231.”
  145. “Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2(4):659-668.”
  146. “Frolov VM, Peresadin NA, Khomutianskaia NI, Pshenichnyi I. The efficacy of quercetin and tocopherol acetate in treating patients with Flexner’s dysentery [in Ukrainian]. Lik Sprava. 1993;4:84-86.”
  147. “Gross M, Pfeiffer M, Martini M, Campbell D, Slavin J, Potter J. The quantitation of metabolites of quercetin flavonols in human urine. Cancer Epidemiol Biomarkers Prevent. 1996;5(9):711-720.”
  148. “Haas EM. Staying Healthy with Nutrition. Berkley, Calif: Celestial Arts Publishing; 1992:272, 882-884.”
  149. “Hollman PC, Van Trijp JM, Mengelers MJ, De Vries JH, Katan, MB. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett. 1997;114(1-2):139-140.”
  150. “Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ (Clinical Research Ed.). 1996;312(7029):478-481.”
  151. “Murray MT. Encyclopedia of Nutritional Supplements. Rocklin, Calif: Prima Publishing; 1996: 320-321.”
  152. “Murray MT, Pizzorno JE. Encyclopedia of Natural Medicine. 2nd ed. Rocklin, Calif: Prima Publishing; 1996:268, 314, 422, 494, 546-47, 766.”
  153. “Shils ME, Olson JA, Shike M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore, Md: Williams & Wilkins; 1999:1274-1277.”
  154. “Werbach MR. Nutritional Influences on Illness. 2nd ed. Tarzana, Calif: Third Line Press; 1993:179, 259, 267, 389.”
  155. “Young JF, Nielsen SE, Haraldsdottir J, et al. Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. Am J Clin Nutr. 1999; 69(1):87-94.”
  156. Abela MB. Hypnotherapy for Crohn’s disease: a promising complementary/alternative therapy. Integr Med.2000;2(2/3):127-131.
  157. Alic M. Green tea for remission maintenance in Crohn’s disease? Am J Gastroenterol.1999;94(6):1710
  158. Anton PA. Stress and mind-body impact on the course of inflammatory bowel diseases. Semin Gastrointest Dis.1999;10(1):14-19.
  159. Ball E. Exercise guidelines for patients with inflammatory bowel disease. Gastroenterol Nurs.1998;21(3):108-111.
  160. “Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr.2000;71(suppl):339S-342S.”
  161. “Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn’s disease patients. Dig Dis Sci.1994;39(12):2589-2594.”
  162. “Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med.1996;334(24):1557-1560.”
  163. “Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231(1):38-45.”
  164. “Blumenthal M, ed. Herbal Medicine. Expanded Commission E Monographs. Newton, Mass: OneMedicine; 2000.”
  165. Bock S. Integrative medical treatment of inflammatory bowel disease. Int J Integr Med. 2000;2(5):21-29.
  166. “Bousvaros A, Zurakowski D, Duggan C. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr . 1998;26:129-135.”
  167. “Brignola C, Belloli C, De Simone G, et al. Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn’s disease. Aliment Pharmacol Ther. 1993;7:275-280.”
  168. “Chowers Y, Sela B, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn’s disease are related to folate levels. Am J Gastroenterol. 2000;95(12):3498-3502.”
  169. “Colombel J, Mathieu D, Bouault J, Lesage X, Zavadil P, Quandelle P, Cortot A. Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis Colon Rectum. 1995;38:609-614.”
  170. “Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120(5):1093-1099.”
  171. “Crohn’s and Colitis Foundation of America. News Updates. Entocortä EC (budesonide) for Crohn’s disease approved by the FDA. October 3, 2001. Accessed at http://www.ccfa.org/news/entocort.htm on October 15, 2001.”
  172. “Dear KL, Hunter JO. Colonoscopic hydrostatic balloon dilation of Crohn’s strictures. J Clin Gastroenterol. 2001;33(4):315-318.”
  173. “Farmer M, Petras RE, Hunt LE, Janosky JE, Galadiuk S. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000; 95(11):3184-3188.”
  174. “Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal ß-D-Galactosidase production and Bifidobacteriaare decreased in Crohn’s disease. Dig Dis Sci.1997;42(4):817-822.”
  175. “Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med. 2000;342:1627-1632.”
  176. “Foster S, Tyler V. Tyler’s Honest Herbal. New York, NY: Haworth Press; 1999:97-99.”
  177. “Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer R-JM. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr. 2000;54:514-521.”
  178. “Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrügger RW, Brummer R-JM. The relation between antioxidant status and alterations in fatty acid profile in patients with Crohn disease and controls. Scand J Gastroenterol. 1999a;34:1108-1116.”
  179. “Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrügger RW, Brummer R-JM. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn’s disease, compared with controls. Am J Gastroenterol. 1999b;94(2):410-417.”
  180. “Geerling BJ, Stockbrugger RW, Brummer R-JM. Nutrition and inflammatory bowel disease: an update. Scand J Gastroenterol. 1999c;34(suppl 230):95-105.”
  181. “Genser D, Kang M-H, Vogelsang H, Elmadfa I. Status of lipidsoluble antioxidants and TRAP in patients with Crohn’s disease and healthy controls. Eur J Clin Nutr.1999;53:675-679.”
  182. “Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhea and inflammatory bowel diseases. J Gastroenterol Hepatol.2000;15:489-493.”
  183. “Glickman RM. Inflammatory bowel disease: ulcerative colitis and Crohn’s disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison’s Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998:1633-1645.”
  184. “Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HPT. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2:37-43.”
  185. “Haas l, McClain C, Varilek G. Complementary and alternative medicine and gastrointestinal diseases. Curr Opin Gastroenterol. 2000;16:188-196.”
  186. “Hampe J, Cuthbert A, Croucher JP, et al. Association between insertion mutation in NOD2 gene Crohn’s disease in German and British populations. Lancet. 2001; 357:1925-1928.”
  187. “Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31(1):8-15.”
  188. “Janowitz HD, Croen EC, Sacher DB. The role of the fecal stream in Crohn’s disease: an historial and analytical review. Inflamm Bowel Dis. 1998;4(1):29-39.”
  189. Joachim G. The relationship between habits of food consumption and reported reactions to food in people with inflammatory bowel disease—testing the limits. Nutr Health. 1999;13(2):69-83.
  190. “Jonas WB, Jacobs J. Healing with Homeopathy: The Doctors’ Guide. New York, NY: Warner Books; 1996: 220.”
  191. “Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.”
  192. “Kuroki F, Iida M, Matsumoto T, Aoyagi K, Kanamoto K, Fujishima M. Serum n3 polyunsaturated fatty acids are depleted in Crohn’s disease. Dig Dis Sci.1997;42(6):1137-1141.”
  193. “Kuroki F, Iida M, Tominaga M, et al. Multiple vitamin status in Crohn’s disease. Dig Dis Sci.1993;38(9):1614-1618.”
  194. “Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol. 1994;19(3):202-205.”
  195. “Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr.2000;71:807-815.”
  196. “Lewis JD, Fisher RL. Nutrition support in inflammatory bowel disease. Med Clin North Am. 1994;78(6):1443-1456.”
  197. “Lih-Brody L, Powell Sr, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci.1996;41(10):2078-2086.”
  198. “Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The effects of physical exercise on patients with Crohn’s disease. Am J Gastroenterol.1999;94(3):697-703.”
  199. “Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with LactobacillusGG. Ann Nutr Metab. 1996;40:137-145.”
  200. “Msika S, Iannelli A, Deroide G, et al. Can laparoscopy reduce hospital stay in the treatment of Crohn’s disease? Dis Colon Rectum. 2001;44(11):1661-1666.”
  201. “Mulder TPJ, Van Der Sluys Veer A, Verspaget HW, et al. Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol.1994;9:472-477.”
  202. “Noyer CM, Brandt LJ. Hyperbaric oxygen therapy for perineal Crohn’s disease. Am J Gastroenterol.1999;94(2):318-321.”
  203. “Pearson M, Teahon K, Levi AJ, Bjarnason. Food intolerance and Crohn’s disease. Gut. 1993;34:783-787.”
  204. “Philipsen-Geerling BJ, Brummer RJM. Nutrition in Crohn’s disease. Curr Opin Clin Nutr Metab Care.2000;3:305-309.”
  205. “Rajapakse R, Korelitz BI. Inflammatory bowel disease during pregnancy. Current Treatment Options in Gastroenterology. 2001;4(3):245-251.”
  206. “Rannem T, Ladefoged K, Hylander E, Hegnhøj J, Staun M. Selenium depletion in patients with gastrointestinal diseases: are there any predictive factors? Scand J Gastroenterol.1998;33:1057-1061.”
  207. “Rawsthorne P, Shanahan F, Cronin NC, et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94(5):1298-1303.”
  208. “Ringel Y, Drossman DA. Psychosocial aspects of Crohn’s disease. Surg Clin North Am.2001;81(1):231-252.”
  209. “Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet. 2001;29:223-228.”
  210. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med. 2000;11(4):191-196.
  211. “Salvatore S, Heuschkel R, Tomlin S, et al. A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in pediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther.2000;14:1567-1579.”
  212. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis.2000;6(2):107-115.
  213. “Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med. 2000;342:1633-1637.”
  214. “Steger GG, Mader RM, Vogelsang H, Schöfl R, Lochs H, Ferenci P. Folate absorption in Crohn’s disease. Digestion. 1994;55:234-238.”
  215. “Stein RB, Lichtenstein GR, Rombeau JL. Nutrition in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care.1999;2:367-371.”
  216. “Szulc P, Meunier PJ. Is vitamin K deficiency a risk factor for osteoporosis in Crohn’s disease? [commentary]. Lancet. 2001;357(9273):1995-1996.”
  217. “Takeshima F, Makiyama K, Doi T. Hyperbaric Oxygen as adjunct therapy for Crohn’s intractable enteric ulcer. Am J Gastroenterol. 1999;94(11):3374-3375.”
  218. “Talal AH, Drossman DA. Psychosocial factors in inflammatory bowel disease. Gastroenterol Clin North Am.1995;24(3):699-716.”
  219. “Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years’ experience with an elemental diet in the management of Crohn’s disease. Gut. 1990;31(10):1133-1137.”
  220. “Tsujikawa T, Satoh J, Katsuhiro U, et al. Clinical importance of n-3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn’s disease. Gastroenterol. 2000;35:99-104.”
  221. “Ullman D. Homeopathic Medicine for Children and Infants. New York, NY: Penguin Putnam; 1992: 244-245.”
  222. “Ullman D. The Consumer’s Guide to Homeopathy.New York, NY: Penguin Putnam; 1995: 76-77.”
  223. “United States Food and Drug Administration (FDA). FDA approves new treatment for Crohn’s disease. FDA Talk Paper. October 3, 2001. Number T01-45.”
  224. “United States Food and Drug Administration (FDA) MedWatch. Remicade (infliximab) – Black Box Warning. October 23, 2001. Accessed at http://www.fda.gov/medwatch/SAFETY/2001/safety01.htm – remicaon October 23, 2001.”
  225. “van Heel DA, McGovern DPB, Jewell DP. Crohn’s disease: a genetic susceptibility, bacteria, and innate immunity [commentary]. Lancet. 2001;357:1902-1903.”
  226. “Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol. 1995;7:609-614.”
  227. “Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease (Cocrane Review). In: The Cochrane Library, 4, 2001. Oxford: Update Software.”
  228. “Zurita VF, Rawls DE, Dyck WP. Nutritional support in inflammatory bowel disease. Dig Dis. 1995;13:92-107.”

Important Patient Links

Pin It on Pinterest

Share This